Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NSE - Delayed Quote INR

Gujarat Themis Biosyn Limited (GUJTHEM.NS)

283.20
-13.40
(-4.52%)
At close: April 25 at 3:30:00 PM GMT+5:30
Loading Chart for GUJTHEM.NS
  • Previous Close 296.60
  • Open 296.55
  • Bid --
  • Ask --
  • Day's Range 280.00 - 305.10
  • 52 Week Range 208.00 - 330.45
  • Volume 144,158
  • Avg. Volume 202,496
  • Market Cap (intraday) 32.287B
  • Beta (5Y Monthly) -0.16
  • PE Ratio (TTM) 58.88
  • EPS (TTM) 4.81
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

www.gtbl.in

159

Full Time Employees

March 31

Fiscal Year Ends

Recent News: GUJTHEM.NS

View More

Performance Overview: GUJTHEM.NS

Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

GUJTHEM.NS
4.95%
S&P BSE SENSEX (^BSESN)
1.37%

1-Year Return

GUJTHEM.NS
4.95%
S&P BSE SENSEX (^BSESN)
6.56%

3-Year Return

GUJTHEM.NS
4.95%
S&P BSE SENSEX (^BSESN)
40.00%

5-Year Return

GUJTHEM.NS
4.95%
S&P BSE SENSEX (^BSESN)
152.86%

Compare To: GUJTHEM.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GUJTHEM.NS

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    30.91B

  • Enterprise Value

    30.77B

  • Trailing P/E

    58.67

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    19.92

  • Price/Book (mrq)

    13.81

  • Enterprise Value/Revenue

    19.84

  • Enterprise Value/EBITDA

    40.61

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    33.96%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.55B

  • Net Income Avi to Common (ttm)

    526.59M

  • Diluted EPS (ttm)

    4.81

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    181.09M

  • Total Debt/Equity (mrq)

    1.52%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: GUJTHEM.NS

View More

Company Insights: GUJTHEM.NS

Research Reports: GUJTHEM.NS

View More

People Also Watch